| Annie Caldwell, LCSW | |
|
2104 Loop Rd Ste C, Winnsboro, LA 71295-3341 | |
| (318) 435-6377 | |
| Not Available |
| Full Name | Annie Caldwell |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 2104 Loop Rd Ste C, Winnsboro, Louisiana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588307268 | NPI | - | NPPES |
| 9705 | Other | LA | LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 9705 (Louisiana) | Primary |
| Entity Name | Franklin Parish Hospital Service District No1 |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619143120 PECOS PAC ID: 7810893302 Enrollment ID: O20031208000235 |
News Archive
Researchers at the University of Pennsylvania School of Medicine report that older adults with diabetes and depression are half as likely to die over a 5-year period when they receive depression care management than depressed patients with diabetes who do not receive depression care management.
Increased serotonergic fibre innervation relative to dopaminergic fibre availability may be a potential marker of disease progression in Parkinson's disease patients and a possible warning of levodopa-induced dyskinesia, indicates an in vivo imaging study.
"In response to rising HIV prevalence, Uganda's government has announced a strategy to reduce new HIV infections by up to 30 percent by 2015, but activists have cast doubt on its ability to achieve this ambitious goal," PlusNews reports.
​Researchers from the Laboratory of Cancer Metabolism (LCM) led by George Thomas at the Bellvitge Biomedical Research Institute (IDIBELL), the Catalan Institute of Oncology (ICO) and the Division of Hematology/ Oncology, University of Cincinnati, have shown that loss of either one of two tumor suppressors, ribosomal proteins RPL5 or RPL11, fail to induce cell-cycle arrest, but prevent the proliferation of cells as they have a reduced capacity to synthesize proteins.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B/2 dose-ranging clinical study with its anticoagulant reversing agent, PMX-60056. The study is intended to demonstrate the safety and efficacy of PMX-60056 in reversing varying heparin levels, including the highest levels commonly used in surgical settings.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Annie Caldwell, LCSW 2104 Loop Rd Ste C, Winnsboro, LA 71295-3341 Ph: (318) 435-6377 | Annie Caldwell, LCSW 2104 Loop Rd Ste C, Winnsboro, LA 71295-3341 Ph: (318) 435-6377 |
News Archive
Researchers at the University of Pennsylvania School of Medicine report that older adults with diabetes and depression are half as likely to die over a 5-year period when they receive depression care management than depressed patients with diabetes who do not receive depression care management.
Increased serotonergic fibre innervation relative to dopaminergic fibre availability may be a potential marker of disease progression in Parkinson's disease patients and a possible warning of levodopa-induced dyskinesia, indicates an in vivo imaging study.
"In response to rising HIV prevalence, Uganda's government has announced a strategy to reduce new HIV infections by up to 30 percent by 2015, but activists have cast doubt on its ability to achieve this ambitious goal," PlusNews reports.
​Researchers from the Laboratory of Cancer Metabolism (LCM) led by George Thomas at the Bellvitge Biomedical Research Institute (IDIBELL), the Catalan Institute of Oncology (ICO) and the Division of Hematology/ Oncology, University of Cincinnati, have shown that loss of either one of two tumor suppressors, ribosomal proteins RPL5 or RPL11, fail to induce cell-cycle arrest, but prevent the proliferation of cells as they have a reduced capacity to synthesize proteins.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B/2 dose-ranging clinical study with its anticoagulant reversing agent, PMX-60056. The study is intended to demonstrate the safety and efficacy of PMX-60056 in reversing varying heparin levels, including the highest levels commonly used in surgical settings.
› Verified 2 days ago
John Quitman Gowan, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 2104 Loop Rd Ste C, Winnsboro, LA 71295 Phone: 318-435-6377 | |
Ms. Jean Anne Black, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2104 Loop Rd, Suite C, Winnsboro, LA 71295 Phone: 318-435-4571 | |
Ms. Lawana Brown, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2106 Loop Rd, Winnsboro, LA 71295 Phone: 318-412-5265 Fax: 318-435-3842 | |
Christy Ticheli, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2106 Loop Rd, Winnsboro, LA 71295 Phone: 318-435-6377 Fax: 318-435-3842 | |
Julia G Green, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2106 Loop Road, Winnsboro, LA 71295 Phone: 318-435-9411 | |
Mr. James Edward Smith, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1301-b Landis Street, Winnsboro, LA 71295 Phone: 318-435-2146 Fax: 318-435-2134 |